SAR 407899

Drug Profile

SAR 407899

Alternative Names: SAR407899; SAR407899A

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Analgesics; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Syndrome X
  • Discontinued Diabetic nephropathies; Diabetic neuropathies; Erectile dysfunction; Hypertension; Kidney disorders; Pulmonary hypertension

Most Recent Events

  • 07 Aug 2017 Sanofi plans a phase II trial for Syndrome X (NCT03236311)
  • 02 May 2013 Phase-I clinical trials in Pulmonary hypertension in Europe (PO)
  • 07 Mar 2013 Discontinued - Phase-I for Diabetic nephropathies in France (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top